Rallybio Corporation Announces Pricing of Initial Public Offering
Rallybio Corporation (Rallybio), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today announced the pricing of its initial public offering of 6,200,000 shares of common stock at a public offering price of $13.00 per share.
- Rallybio Corporation (Rallybio), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today announced the pricing of its initial public offering of 6,200,000 shares of common stock at a public offering price of $13.00 per share.
- The gross proceeds of the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Rallybio, are expected to be approximately $80.6 million.
- The offering is expected to close on August 2, 2021, subject to the satisfaction of customary closing conditions.
- In addition, Rallybio has granted the underwriters a 30-day option to purchase up to an additional 930,000 shares of common stock at the initial public offering price, less underwriting discounts and commissions.